Q2 Earnings Forecast for Harrow Issued By William Blair

Harrow, Inc. (NASDAQ:HROW - Free Report) - Equities researchers at William Blair issued their Q2 2025 earnings estimates for Harrow in a research report issued to clients and investors on Tuesday, June 10th. William Blair analyst L. Hanbury-Brown expects that the company will post earnings per share of $0.00 for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow's Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.37 EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at $1.35 EPS.

A number of other research firms have also commented on HROW. BTIG Research started coverage on shares of Harrow in a research report on Thursday. They issued a "buy" rating and a $62.00 price target on the stock. HC Wainwright raised their target price on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. Finally, B. Riley decreased their target price on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $61.40.

Harrow Stock Performance

HROW traded down $0.45 during trading on Thursday, hitting $31.16. The stock had a trading volume of 332,618 shares, compared to its average volume of 501,650. The company has a 50 day simple moving average of $26.00 and a 200-day simple moving average of $29.77. Harrow has a 12 month low of $16.87 and a 12 month high of $59.23. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The firm has a market cap of $1.14 billion, a PE ratio of -33.15 and a beta of 0.40.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). The business had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%.

Institutional Trading of Harrow

Large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new position in Harrow in the 4th quarter worth about $25,000. Quarry LP purchased a new stake in Harrow during the 1st quarter valued at approximately $32,000. Tower Research Capital LLC TRC boosted its position in shares of Harrow by 769.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after acquiring an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in Harrow in the fourth quarter worth $78,000. Finally, State of Wyoming bought a new stake in Harrow in the first quarter worth $97,000. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.